ESH MM 2018 | Emerging treatments for myeloma: quadruplets, bispecific antibodies & CAR T-cells
Heinz Ludwig
• 5 Oct 2018
New therapeutic developments for multiple myeloma (MM) are showing promising results in clinical trials. Here, Heinz Ludwig, MD, PhD, from Wilhelminen Cancer Research Institute, Vienna, Austria, discusses emerging therapies for MM treatment, including quadruplet regimens, bispecifc antibodies and CAR T-cells. Speaking from the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France, Dr Ludwig highlights the need for further studies to determine the efficacy profile of bispecific antibodies in MM, as well as the need to develop an optimal strategy for CAR T-cells.
